Update shared on15 Aug 2025
Fair value Increased 9.52%Journey Medical’s sharply improved net profit margin and lower future P/E ratio signal enhanced profitability and valuation appeal, driving the consensus analyst price target up from $10.50 to $11.50.
What's in the News
- Pharmacy benefit coverage for Emrosi™ increased to 65% of US commercial lives, up from 29% in May.
- Analysis from two Phase 3 trials shows Emrosi efficacy is not affected by body weight, supporting its approval as the lowest oral dose minocycline for rosacea.
- Emrosi clinical data will be presented at the Society of Dermatology Physician Associates 2025 Summer Conference.
- Journey Medical approved a Fourth Amended and Restated Charter providing officer exculpation.
- Added to multiple Russell growth and small cap indices, including Russell 2000, 2500, 3000, and Small Cap Completeness.
Valuation Changes
Summary of Valuation Changes for Journey Medical
- The Consensus Analyst Price Target has risen from $10.50 to $11.50.
- The Net Profit Margin for Journey Medical has significantly risen from 33.03% to 47.47%.
- The Future P/E for Journey Medical has significantly fallen from 6.22x to 4.57x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.